Another vaccine candidate appears to safely induce an immune reaction opposed to coronavirus, initial results.
The candidate, developed through researchers from the University of Oxford and the pharmaceutical apple AstraZeneca, is the sign of hope that scientists can identify a vaccine capable of preventing the COVID-1nine pandemic.
A clinical trial of 1,077 healthy adults found that the vaccine can also cause a strong immune reaction in antibodies and T cells up to the 56th day of the study. Data from a sub-organization of 10 participants also anticipated that a momentary dose would cause an even greater reaction to SARS-CoV-2.
No serious adverse extractions were reported to the vaccine, but it caused minor side effects than the meningitis vaccine administered in the control group. The effects were published Monday in The Lancet.
Last week, Moderna launched promising effects of its vaccine, which is expected to begin soon a Phase 3 trial. Several other candidate vaccines have also been transferred to phase 3 trials, adding one through Pfizer and BioNTech.
The Oxford vaccine has always generated enthusiasm, despite the willingness to conduct further studies. U.S. governments And Britain and the European alliance have put a number of millions of doses in order.
The vaccine caused a reaction to coronavirus on two fronts. First, it caused a T-cell reaction to 1 quarter of vaccination. T cell phones locate and attack the coronavirus when it invades the cell phones.
It also triggered the production of antibodies, at the time when a defensive line of the immune formula opposed the invaders, in the case of 28 days of vaccination.
“The immune formula has two tactics for discanopia and pathogen attack: antibodies and T-cell responses,” said Oxford University researcher Andrew Pollard, the study’s leader. “This vaccine is intended to urge both, so that it can attack the virus as it circulates through the body, as well as inflamed cells. We hope this indicates that the immune formula will not forget the virus, so our vaccine will protect other Americans for a longer era of time.
“However, we prefer more studies before we can analyze the vaccine’s ability to protect the vaccine well from SARS-CoV-2 infection and how long an apple policy lasts.”
Study participants, aged 18 to 55, won the hot vaccine or meningitis vaccine. They were then asked to produce blood samples and go through clinical evaluations to the safety and efficacy of the vaccine.
Fatigue and headaches were side effects. Others included injection site pain, muscle pain, chills and fever. A sub-organization asked to take acetaminophen before or after vaccination in the country reported a negative effect on the aspects. Study participants will continue to be followed for one year.
The next step is to conduct further clinical studies, including in older adults, to confirm that the vaccine does confer protection. A Phase 2 trial is happening in the United Kingdom and a Phase 3 trial in the U.K., Brazil and South Africa. The U.S. also plans on conducting clinical trials on the vaccine later this summer.
According to the World Health Organization, 23 COVID-1 vaccines are being tested in humans.
He and its contents are provided “as is”.